Clear Search

Showing 1 result for “Daniels GH” published 2022.

January 2022

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

N Engl J Med 2016;375:311–22 DOI: 10.1056/NEJMoa1603827

The LEADER trial demonstrated CV benefits with liraglutide, and showed that the rate of the first occurrence of death from cardiovascular (CV) causes, nonfatal myocardial infarction (MI), or nonfatal stroke among patients with type 2 diabetes (T2D) was lower with liraglutide than with placebo.

more…